Next Arc Research

Not logged in? You're viewing the Free tier. Join for free or log in to access your membership content.
Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.
Disclosure: The author does not hold a position in CRSP.
← Back to Free Index

CRSP

Analysis as of: 2026-08-07
CRISPR Therapeutics AG
CRISPR Therapeutics develops gene-edited medicines, led by CASGEVY with Vertex and a pipeline spanning in vivo editing, cell therapy, and regenerative medicine.
biotech healthcare
On Yahoo Finance ...
Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

Approved edit, unproven platform, real rerating path
The approved franchise gives the company time and credibility, but the stock’s next leg depends on proving at least one wholly owned branch can become a durable commercial asset by 2031. That makes the setup asymmetric, yet still constrained by clinical and commercial proof gates.

Analysis

Thesis
CRISPR Therapeutics has already crossed the hardest trust gate with an approved CRISPR therapy; if CASGEVY converts access into steadier economics and just one wholly owned branch such as CTX310 or zugo-cel becomes commercially credible, the company can rerate from cash-backed science optionality into a multi-franchise gene-medicine platform by 2031.
Last Economy Alignment
AI lowers discovery and design cost, but CRISPR captures value mainly through regulated approvals, IP, manufacturing, and clinical data that are hard to commoditize. The main drag is that CASGEVY’s flagship commercial surface is still partly controlled by Vertex.
Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple
2.5x (from 5 most recent analyses)
Reasoning
This is an asymmetric but still bounded setup. The approved franchise buys time and credibility, while multiple owned shots can create a rerating without needing every program to work. If CASGEVY becomes a steadier commercial engine and one owned cardiometabolic or cell-therapy asset looks launchable, investors can value the company as a repeatable gene-medicine builder rather than as one approved asset plus cash and science risk.
Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary
The key risk is proof conversion, not immediate funding. CRISPR must turn CASGEVY from promising access momentum into repeatable economics and show at least one wholly owned program with durable efficacy, clean enough safety, and a workable launch path; otherwise the stock can stay trapped as a partner-mediated approved asset plus a pipeline the market values mainly as scientific optionality.
Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Last Economy Structure

AI Industrial Score
0.53
They own hard-to-copy drug approvals, manufacturing know-how, and gene-editing IP, so faster AI mostly helps them design and iterate better rather than replacing them. The risk is that biology, regulators, and a partner-controlled launch still decide how much of that value they actually keep.
Upgrade to Reader to also access: Score Decomposition, Confidence Level
Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility
Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target
$87.56
Upgrade to Reader to also access: Bull Case, Base Case, Bear Case